Vraylar: A New Medication FDA Approved to Treat Bipolar Disorder and Schizophrenia
Vraylar is the newest medication FDA approved to treat acute manic or mixed episode associated with Bipolar I Disorder. When comparing it to placebo, it had a 69% improvement in treating a manic episode of Bipolar Disorder in the dosing range from 3 to 12 mg/day.
Vraylar had differing efficacy depending on the dosage when used to treat patients with Schizophrenia. It had a 64% improvement over placebo in the dose of 1.5 mg. It had a 75% improvement over placebo in the 3 mg dose and a 89% improvement over placebo in the dose of 4.5 mg.
Treating Mania and Schizophrenia with Minimal Side Effects
Furthermore, the side effects of using Vraylar tend to be minimal. As far as weight gain is concerned, there was risk of weight gain of 1.1 lbs in comparison to placebo risk of weight gain of 0.4 lbs in those with Bipolar mania and the risk to patients with Schizophrenia it was 1.8 lbs in the dose range 1.5 to 3 mg/day or 2.2 lbs gained with the group dosed at 4.5 to 6 mg/day in comparison to placebo 0.7 lbs gained.
Vraylar is in the group of Atypical anti-psychotics that have caused Hyperglycemia and Diabetes Mellitus, Dyslipidemia, nevertheless, the risks with these conditions happening was similar to placebo. There are other side effects that may occur and this is not an exhaustive list.
One more common side effect that I have noticed in the patients that I have treated with Vraylar is Akathesia, which is an inner feeling of restlessness that makes one need to get up and walk around. This can been mitigated by the use of a medication that minimizes this side effect, if needed. The difference between this occurring and placebo was 20% vs. 5%.